Your browser doesn't support javascript.
loading
Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease.
Paulides, Emma; Pasma, Annelieke; Erler, Nicole S; van Eijk, Rachel L A; de Vries, Annemarie C; van der Woude, C Janneke.
Affiliation
  • Paulides E; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. e.paulides@erasmusmc.nl.
  • Pasma A; Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Erler NS; Department of Biostatistics, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • van Eijk RLA; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • de Vries AC; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • van der Woude CJ; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Dig Dis Sci ; 67(7): 2849-2856, 2022 07.
Article in En | MEDLINE | ID: mdl-34181168
BACKGROUND: To learn from the crisis caused by the coronavirus disease (COVID-19) pandemic and be prepared for future pandemics, it is important to investigate the impact of this period on the wellbeing of patients with inflammatory bowel disease (IBD). AIMS: To describe the health-related quality of life (HRQoL) and disease control of IBD patients during the first wave of the COVID-19 pandemic in The Netherlands. METHODS: Between March 17 and July 1, 2020, patients aged 18 years and older with IBD from the Erasmus MC (Rotterdam, The Netherlands) were invited to complete online questionnaires at week 0, 2, 6 and 12. The Inflammatory Bowel Disease Questionnaire (IBDQ), the Inflammatory Bowel Disease Control-8 (IBD-control-8) and the numeric rating scale on fatigue were used. The evolution of the different outcomes over time was measured using mixed models. RESULTS: Of 1151 invited patients, 851 patients (67% CD and 33% UC or IBD-U) participated in the study (response rate 74%). No relevant changes in total scores were found over time for the IBDQ (effect estimate 0.006, 95% CI [- 0.003 to 0.015]) and IBD-control-8 (effect estimate 0.004, 95% CI [0.998-1.011]). There was a slight, increasing trend in fatigue scores over time (effect estimate 0.011, 95% CI [0.004, 0.019]). CONCLUSIONS: This first lock down due to the COVID-19 pandemic in The Netherlands did not impact on the HRQoL and disease control of patients with IBD. Up to date information may have contributed to a stable HRQoL in IBD patients even in an extreme period with restrictions and insecurities.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Inflammatory Bowel Diseases / COVID-19 Type of study: Etiology_studies / Prognostic_studies Limits: Humans Language: En Journal: Dig Dis Sci Year: 2022 Type: Article Affiliation country: Netherlands

Full text: 1 Database: MEDLINE Main subject: Inflammatory Bowel Diseases / COVID-19 Type of study: Etiology_studies / Prognostic_studies Limits: Humans Language: En Journal: Dig Dis Sci Year: 2022 Type: Article Affiliation country: Netherlands